New drug combo shows promise against tough breast cancer
NCT ID NCT07544056
First seen May 02, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests whether adding the experimental drug BEBT-209 to standard chemotherapy (carboplatin and gemcitabine) works better than chemotherapy alone for people with advanced triple-negative breast cancer. About 446 women aged 18-75 will be randomly assigned to one of two groups. The goal is to see if the combination shrinks tumors and helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.